Cancer Therapy

Celgene offers promising preclinical data on two cytokine inhibitors

Published in Vaccine Weekly, May 8th, 2002

Celgene Corp. (CELG) scientists presented data at the 93rd annual meeting of the American Association for Cancer Research from preclinical studies of IMiDs (Immunomodulatory Drugs) and SelCIDs (Selective Cytokine Inhibitory Drugs); the data demonstrate that IMiDs and SelCIDs have significant antitumor effects in in vivo models of solid tumor cancers.

"These findings validate our decision to accelerate the clinical development programs for our IMiD and SelCID pipelines in cancer," said David I. Stirling, PhD, chief scientific officer of Celgene Corp. "These data also provide valuable mechanistic insight as to how these two classes of orally available, anticancer...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-05-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry